Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Long-term benefits with molnupiravir modest at best in COVID-19 treatment

Long-term benefits with molnupiravir modest at best in COVID-19 treatment

24 Sep 2024 bởiJairia Dela Cruz

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.

Long-term benefits with molnupiravir modest at best in COVID-19 treatment

24 Sep 2024
Long-term freedom from insulin may be achieved with duodenal electroporation plus semaglutide

Long-term freedom from insulin may be achieved with duodenal electroporation plus semaglutide

23 Sep 2024
What fuels flu, pneumococcal vaccine hesitancy in SG?

What fuels flu, pneumococcal vaccine hesitancy in SG?

23 Sep 2024 bởiJairia Dela Cruz

In Singapore, influenza and pneumococcal vaccination coverage remains stubbornly low. Results of two separate analysis of a cross-sectional survey shed light on this concerning trend, highlighting the roles of vaccine knowledge and attitude, healthcare professionals, and social support in influencing vaccination decisions.

What fuels flu, pneumococcal vaccine hesitancy in SG?

23 Sep 2024